Emmanuel Agoh, MD
General Practice · Houston, TXNPI 1508034927
Payments from drug & device makers
Across 503 payments — averaging $19.25 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- GSK$2K
- AstraZeneca$2K
- Bayer$751
- Pfizer$692
- Gilead$522
- Merck$408
- plus $4K from 31 others
What the payments were for
- Food & beverage$9,655100%
- Education$280%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| GSK | 119 | $1,854 |
| AstraZeneca | 66 | $1,719 |
| Bayer | 47 | $751 |
| Pfizer | 40 | $692 |
| Gilead | 18 | $522 |
| Merck | 25 | $408 |
| Boehringer Ingelheim | 19 | $358 |
| Viiv Healthcare Company | 3 | $337 |
| Lilly USA, LLC | 16 | $301 |
| Sunovion Pharmaceuticals Inc. | 23 | $295 |
| Novartis | 18 | $291 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 10 | $253 |
| Johnson & Johnson | 12 | $224 |
| Astellas Pharma US Inc | 11 | $205 |
| Novo Nordisk | 6 | $188 |
| AbbVie(2 entities) | 8 | $158 |
| Vanda Pharmaceuticals Inc. | 8 | $155 |
| Teva Pharmaceuticals USA, Inc. | 6 | $123 |
| Dexcom, Inc. | 7 | $123 |
| Amgen(2 entities) | 6 | $107 |
| Sumitomo Pharma America, Inc. | 5 | $86 |
| Esperion Therapeutics, Inc. | 5 | $84 |
| Viatris Specialty LLC | 4 | $81 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 4 | $54 |
| Cipher Pharmaceuticals US LLC | 1 | $39 |
| Hologic Sales And Service, LLC | 2 | $37 |
| Exact Sciences | 2 | $35 |
| Abbott | 2 | $35 |
| Phathom Pharmaceuticals, Inc. | 2 | $34 |
| Xeris Pharmaceuticals, Inc. | 1 | $24 |
| Ironwood Pharmaceuticals, Inc | 1 | $22 |
| Medtronic | 1 | $17 |
| Mylan Specialty L.p. | 1 | $17 |
| Avanir Pharmaceuticals, Inc. | 1 | $15 |
| Scilex Pharmaceuticals Inc. | 1 | $14 |
| Eisai Inc. | 1 | $13 |
| Arbor Pharmaceuticals, Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$9,684 in reported general payments places this provider in the 95th percentile of 8,074 general practice providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 226 | $301,931 |
| OzempicSemaglutide | 153 | $278,607 |
| EliquisApixaban | 224 | $252,676 |
| MounjaroTirzepatide | 122 | $203,939 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 177 | $176,009 |
| BiktarvyBictegrav/Emtricit/Tenofov Ala | 34 | $142,763 |
| EntrestoSacubitril/Valsartan | 99 | $114,060 |
| XareltoRivaroxaban | 71 | $92,655 |
| FarxigaDapagliflozin Propanediol | 70 | $88,686 |
| TivicayDolutegravir Sodium | 35 | $81,985 |
| TriumeqAbacavir/Dolutegravir/Lamivudi | 18 | $70,212 |
| LinzessLinaclotide | 76 | $57,809 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 949 | $51,843 |
| TrulicityDulaglutide | 22 | $43,671 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 34 | $41,902 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimJardiance, Combivent Respimat, Tradjenta, Spiriva Respimat | $358 | $358,180282 claims |
| Novo NordiskOzempic | $188 | $278,607153 claims |
| PfizerEliquis | $692 | $252,676224 claims |
| Lilly USA, LLCMounjaro, Trulicity | $301 | $247,610144 claims |
| GSKTrelegy Ellipta | $1,854 | $176,009177 claims |
| GileadBiktarvy, Descovy | $522 | $167,06145 claims |
| AstraZenecaFarxiga, Breztri Aerosphere, Symbicort, Brilinta | $1,719 | $161,814181 claims |
| Viiv Healthcare CompanyTivicay, Triumeq | $337 | $152,19653 claims |
| Johnson & JohnsonXarelto, Prezcobix | $224 | $119,85182 claims |
| NovartisEntresto | $291 | $114,06099 claims |
| MerckJanuvia, Janumet Xr, Janumet | $408 | $61,18562 claims |
| AbbVieLinzess | $158 | $57,80976 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 8,074 general practice providers in Texas.
Other general practice in Houston
- Helen ShpatsHouston$3.3M
- Kelechi AzuoguHouston$2.5M
- Kathleen Szelei-StevensHouston$253K
- Zsolt GaramiHouston$111K
- Jesus MayorHouston$105K
- Azim KarimHouston$98K
- Scott ColemanHouston$87K
- Rispba McCray-GarrisonHouston$70K
- Piya GandhiHouston$36K
- Terri AlaniHouston$30K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.